Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

37.74 -0.28 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 400,041
Open 38.43
Bid (Size) 37.71 (700)
Ask (Size) 37.74 (800)
Prev. Close 38.02
Today's Range 37.26 - 38.62
52wk Range 13.76 - 38.57
Shares Outstanding 25,688,062
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton (ETON) Q1 2026 Earnings Call Transcript ↗
Eton (ETON) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+132.1%
+132.1%
1 Month
+26.0%
+26.0%
3 Month
+51.0%
+51.0%
6 Month
+125.6%
+125.6%
1 Year
+162.3%
+162.3%

More News

Read More
News headline image
Eton Pharmaceuticals Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Eton Pharmaceuticals (NASDAQ:ETON) Soars on Q1 Beat, Raises Full-Year Guidance ↗
Via Chartmill
Eton Pharmaceuticals (NASDAQ:ETON) Posts Mixed Q4 2025 Results with Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
Via Benzinga
News headline image
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces CFO Succession Plan
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharma (ETON) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
ETON PHARMACEUTICALS INC (NASDAQ:ETON) Reports Q3 2025 Revenue Beat and EPS Miss ↗
Via Chartmill
News headline image
Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
From Eton Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Eton Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Eton Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Eton Pharmaceuticals, Inc. - Common Stock trade on?
Eton Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Eton Pharmaceuticals, Inc. - Common Stock is ETON on the Nasdaq Stock Market
What is the current price of Eton Pharmaceuticals, Inc. - Common Stock?
The current price of Eton Pharmaceuticals, Inc. - Common Stock is 37.74
When was Eton Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Eton Pharmaceuticals, Inc. - Common Stock was at 07/07/26 04:00 PM ET
What is the market capitalization of Eton Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Eton Pharmaceuticals, Inc. - Common Stock is 969.47M
How many shares of Eton Pharmaceuticals, Inc. - Common Stock are outstanding?
Eton Pharmaceuticals, Inc. - Common Stock has 969M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.